This company listing is no longer active
MorphoSys Gelecekteki Büyüme
Future kriter kontrolleri 2/6
MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.
Anahtar bilgiler
59.1%
Kazanç büyüme oranı
78.2%
EPS büyüme oranı
Biotechs kazanç büyümesi | 27.1% |
Gelir büyüme oranı | 25.0% |
Gelecekteki özkaynak getirisi | 7.7% |
Analist kapsamı | Good |
Son güncelleme | 05 Aug 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
MorphoSys: Hold Rating Until The Novartis Deal Closes
May 01Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 425 | -78 | -120 | -50 | 5 |
12/31/2025 | 322 | -140 | -236 | -201 | 8 |
12/31/2024 | 180 | -249 | -296 | -253 | 3 |
3/31/2024 | 241 | -469 | -286 | -284 | N/A |
12/31/2023 | 238 | -190 | -299 | -296 | N/A |
9/30/2023 | 223 | 104 | -363 | -355 | N/A |
6/30/2023 | 255 | 100 | -349 | -338 | N/A |
3/31/2023 | 261 | -61 | -321 | -306 | N/A |
12/31/2022 | 278 | -151 | -382 | -367 | N/A |
9/30/2022 | 250 | -861 | -436 | -417 | N/A |
6/30/2022 | 195 | -851 | -606 | -588 | N/A |
3/31/2022 | 174 | -596 | -610 | -583 | N/A |
12/31/2021 | 180 | -514 | -508 | -481 | N/A |
9/30/2021 | 163 | -150 | -423 | -393 | N/A |
6/30/2021 | 143 | -103 | -295 | -246 | N/A |
3/31/2021 | 124 | -177 | -255 | -217 | N/A |
12/31/2020 | 328 | 98 | -14 | 35 | N/A |
9/30/2020 | 303 | 64 | 26 | 63 | N/A |
6/30/2020 | 293 | 105 | 98 | 113 | N/A |
3/31/2020 | 309 | 153 | 137 | 152 | N/A |
12/31/2019 | 72 | -103 | -85 | -81 | N/A |
9/30/2019 | 71 | -96 | -68 | -64 | N/A |
6/30/2019 | 114 | -42 | -42 | -39 | N/A |
3/31/2019 | 87 | -59 | -33 | -31 | N/A |
12/31/2018 | 76 | -56 | -35 | -33 | N/A |
9/30/2018 | 94 | -27 | -16 | -14 | N/A |
6/30/2018 | 54 | -82 | -61 | -48 | N/A |
3/31/2018 | 58 | -74 | -68 | -55 | N/A |
12/31/2017 | 67 | -70 | N/A | -38 | N/A |
9/30/2017 | 52 | -84 | N/A | -52 | N/A |
6/30/2017 | 49 | -73 | N/A | -59 | N/A |
3/31/2017 | 49 | -68 | N/A | -47 | N/A |
12/31/2016 | 50 | -60 | N/A | -47 | N/A |
9/30/2016 | 49 | -45 | N/A | -48 | N/A |
6/30/2016 | 48 | -40 | N/A | -41 | N/A |
3/31/2016 | 48 | -33 | N/A | -35 | N/A |
12/31/2015 | 106 | 15 | N/A | -24 | N/A |
9/30/2015 | 111 | 27 | N/A | -15 | N/A |
6/30/2015 | 116 | 33 | N/A | -3 | N/A |
3/31/2015 | 119 | 37 | N/A | -4 | N/A |
12/31/2014 | 64 | -3 | N/A | -14 | N/A |
9/30/2014 | 61 | -6 | N/A | -15 | N/A |
6/30/2014 | 60 | -5 | N/A | 79 | N/A |
3/31/2014 | 77 | 7 | N/A | 76 | N/A |
12/31/2013 | 78 | 7 | N/A | 89 | N/A |
9/30/2013 | 80 | 14 | N/A | 100 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: MOR is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: MOR is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: MOR is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: MOR's revenue (25% per year) is forecast to grow faster than the US market (8.5% per year).
Yüksek Büyüme Geliri: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).